Davangere Sugar Company Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 6, 2025, 12:23 am

Quick Insight

The financial metrics of Davangere Sugar Company Ltd reveal a mixed picture. With a P/E ratio of 41.9, the market seems to have high expectations for future earnings growth. However, the low ROE and ROCE figures of 3.22% and 6.80% respectively indicate inefficiency in capital utilization. The high operating profit margin of 47.32% is a positive sign of operational efficiency, but the company's net profit of 11 Cr. seems relatively low compared to its market capitalization of 473 Cr. Additionally, the high level of borrowings at ₹282 Cr. raises concerns about the company's leverage. Overall, investors should closely monitor the company's ability to improve profitability and reduce debt to enhance shareholder value in the long run.

Competitors of Davangere Sugar Company Ltd

All Competitor Stocks of Davangere Sugar Company Ltd

Quarterly Result

Last Updated: August 19, 2025, 8:25 pm

Below is a detailed analysis of the quarterly data for Davangere Sugar Company Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 24.07 Cr.. The value appears to be declining and may need further review. It has decreased from 56.91 Cr. (Mar 2025) to 24.07 Cr., marking a decrease of 32.84 Cr..
• For Expenses, as of Jun 2025, the value is 12.68 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 47.23 Cr. (Mar 2025) to 12.68 Cr., marking a decrease of 34.55 Cr..
• For Operating Profit, as of Jun 2025, the value is 11.39 Cr.. The value appears strong and on an upward trend. It has increased from 9.68 Cr. (Mar 2025) to 11.39 Cr., marking an increase of 1.71 Cr..
• For OPM %, as of Jun 2025, the value is 47.32%. The value appears strong and on an upward trend. It has increased from 17.01% (Mar 2025) to 47.32%, marking an increase of 30.31%.
• For Other Income, as of Jun 2025, the value is 0.46 Cr.. The value appears to be declining and may need further review. It has decreased from 0.57 Cr. (Mar 2025) to 0.46 Cr., marking a decrease of 0.11 Cr..
• For Interest, as of Jun 2025, the value is 6.95 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.32 Cr. (Mar 2025) to 6.95 Cr., marking an increase of 2.63 Cr..
• For Depreciation, as of Jun 2025, the value is 3.18 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3.68 Cr. (Mar 2025) to 3.18 Cr., marking a decrease of 0.50 Cr..
• For Profit before tax, as of Jun 2025, the value is 1.72 Cr.. The value appears to be declining and may need further review. It has decreased from 2.25 Cr. (Mar 2025) to 1.72 Cr., marking a decrease of 0.53 Cr..
• For Tax %, as of Jun 2025, the value is 24.42%. The value appears to be increasing, which may not be favorable. It has increased from 13.33% (Mar 2025) to 24.42%, marking an increase of 11.09%.
• For Net Profit, as of Jun 2025, the value is 1.30 Cr.. The value appears to be declining and may need further review. It has decreased from 1.94 Cr. (Mar 2025) to 1.30 Cr., marking a decrease of 0.64 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.01. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: May 15, 2025, 3:50 am

Growth

Last Updated: September 5, 2025, 3:06 pm

Balance Sheet

Last Updated: July 25, 2025, 1:28 pm

Below is a detailed analysis of the balance sheet data for Davangere Sugar Company Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2024, the value is 94.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 94.00 Cr..
• For Reserves, as of Sep 2024, the value is 248.00 Cr.. The value appears strong and on an upward trend. It has increased from 246.00 Cr. (Mar 2024) to 248.00 Cr., marking an increase of 2.00 Cr..
• For Borrowings, as of Sep 2024, the value is 282.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 264.00 Cr. (Mar 2024) to 282.00 Cr., marking an increase of 18.00 Cr..
• For Other Liabilities, as of Sep 2024, the value is 97.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 78.00 Cr. (Mar 2024) to 97.00 Cr., marking an increase of 19.00 Cr..
• For Total Liabilities, as of Sep 2024, the value is 721.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 682.00 Cr. (Mar 2024) to 721.00 Cr., marking an increase of 39.00 Cr..
• For Fixed Assets, as of Sep 2024, the value is 357.00 Cr.. The value appears to be declining and may need further review. It has decreased from 359.00 Cr. (Mar 2024) to 357.00 Cr., marking a decrease of 2.00 Cr..
• For CWIP, as of Sep 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Sep 2024, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 5.00 Cr..
• For Other Assets, as of Sep 2024, the value is 360.00 Cr.. The value appears strong and on an upward trend. It has increased from 318.00 Cr. (Mar 2024) to 360.00 Cr., marking an increase of 42.00 Cr..
• For Total Assets, as of Sep 2024, the value is 721.00 Cr.. The value appears strong and on an upward trend. It has increased from 682.00 Cr. (Mar 2024) to 721.00 Cr., marking an increase of 39.00 Cr..

However, the Borrowings (282.00 Cr.) are higher than the Reserves (248.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

No data available for the No. of Shareholders chart.

Key Financial Ratios

After reviewing the key financial ratios for Davangere Sugar Company Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 1.00, marking a decrease of 9.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 1.16. This value is below the healthy minimum of 5. It has decreased from 1.30 (Mar 24) to 1.16, marking a decrease of 0.14.
• For Diluted EPS (Rs.), as of Mar 25, the value is 1.16. This value is below the healthy minimum of 5. It has decreased from 1.30 (Mar 24) to 1.16, marking a decrease of 0.14.
• For Cash EPS (Rs.), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 3. It has decreased from 2.57 (Mar 24) to 0.25, marking a decrease of 2.32.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 3.72. It has decreased from 36.14 (Mar 24) to 3.72, marking a decrease of 32.42.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 3.72. It has decreased from 36.14 (Mar 24) to 3.72, marking a decrease of 32.42.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 2.29. It has decreased from 23.02 (Mar 24) to 2.29, marking a decrease of 20.73.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 2. It has decreased from 5.35 (Mar 24) to 0.57, marking a decrease of 4.78.
• For PBIT / Share (Rs.), as of Mar 25, the value is 0.43. This value is within the healthy range. It has decreased from 4.08 (Mar 24) to 0.43, marking a decrease of 3.65.
• For PBT / Share (Rs.), as of Mar 25, the value is 0.13. This value is within the healthy range. It has decreased from 1.53 (Mar 24) to 0.13, marking a decrease of 1.40.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 0.11. This value is below the healthy minimum of 2. It has decreased from 1.30 (Mar 24) to 0.11, marking a decrease of 1.19.
• For PBDIT Margin (%), as of Mar 25, the value is 25.00. This value is within the healthy range. It has increased from 23.23 (Mar 24) to 25.00, marking an increase of 1.77.
• For PBIT Margin (%), as of Mar 25, the value is 19.09. This value is within the healthy range. It has increased from 17.70 (Mar 24) to 19.09, marking an increase of 1.39.
• For PBT Margin (%), as of Mar 25, the value is 5.98. This value is below the healthy minimum of 10. It has decreased from 6.67 (Mar 24) to 5.98, marking a decrease of 0.69.
• For Net Profit Margin (%), as of Mar 25, the value is 5.08. This value is within the healthy range. It has decreased from 5.65 (Mar 24) to 5.08, marking a decrease of 0.57.
• For Return on Networth / Equity (%), as of Mar 25, the value is 3.12. This value is below the healthy minimum of 15. It has decreased from 3.60 (Mar 24) to 3.12, marking a decrease of 0.48.
• For Return on Capital Employeed (%), as of Mar 25, the value is 8.47. This value is below the healthy minimum of 10. It has increased from 8.38 (Mar 24) to 8.47, marking an increase of 0.09.
• For Return On Assets (%), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 5. It has decreased from 1.79 (Mar 24) to 1.47, marking a decrease of 0.32.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 0.2. It has decreased from 0.20 (Mar 24) to 0.13, marking a decrease of 0.07.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.77. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.77.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.30. It has decreased from 0.33 (Mar 24) to 0.30, marking a decrease of 0.03.
• For Current Ratio (X), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 1.5. It has increased from 1.33 (Mar 24) to 1.43, marking an increase of 0.10.
• For Quick Ratio (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has increased from 0.78 (Mar 24) to 0.86, marking an increase of 0.08.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.00. This value is below the healthy minimum of 4. It has decreased from 1.18 (Mar 24) to 1.00, marking a decrease of 0.18.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 1.91. This value is below the healthy minimum of 3. It has decreased from 2.11 (Mar 24) to 1.91, marking a decrease of 0.20.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.39. This value is below the healthy minimum of 3. It has decreased from 1.51 (Mar 24) to 1.39, marking a decrease of 0.12.
• For Enterprise Value (Cr.), as of Mar 25, the value is 624.89. It has decreased from 970.55 (Mar 24) to 624.89, marking a decrease of 345.66.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.91. This value is within the healthy range. It has decreased from 4.48 (Mar 24) to 2.91, marking a decrease of 1.57.
• For EV / EBITDA (X), as of Mar 25, the value is 11.63. This value is within the healthy range. It has decreased from 19.30 (Mar 24) to 11.63, marking a decrease of 7.67.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 3.28 (Mar 24) to 1.66, marking a decrease of 1.62.
• For Price / BV (X), as of Mar 25, the value is 1.02. This value is within the healthy range. It has decreased from 2.09 (Mar 24) to 1.02, marking a decrease of 1.07.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 3.28 (Mar 24) to 1.66, marking a decrease of 1.62.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness